Michelle Wagner Gardinier

Strategic leadership and technical guidance of small molecule and biologics discovery programs across Oncology pipeline • Discovery project lead for small molecule covalent inhibitor; designed strategy for hit identification, lead optimization, efficacy and safety studies. • Led multidisciplinary team to progress compounds to lead status with rapid IP filing. • Due diligence activities and review of nonclinical study reports for IND filing of ADC asset.

• Research Program Leader for multiple drug discovery projects utilizing diverse modalities to target novel mechanisms in Oncology in collaboration with academic institutions and industry partners. • Leading project team in active collaboration with academic PIs and various internal Pfizer groups to develop T-cell engaging bispecific antibody for treatment of multiple cancer types. • Leading project team of industry partners and internal Pfizer groups to discover and develop degrader/PROTAC molecules for targets implicated in cancer cell drug resistance. • Leading Pfizer sponsored external research collaboration with academic PI studying potential targets implicated in drug resistance of cancer stem cells. Initiated project proposal and awarded funding for workplan to generate target validation data package to support future drug discovery efforts. • Program leadership to conceive, compose and present project proposals, workplans, and timelines. Foster communication among multiple stakeholders and coordination of diverse efforts to guide experiments and resourcing to ensure project progression. • Management of CTI Research Scientists supporting project teams with reagent validation, assay development, and proof of concept experiments. • Due diligence to review and provide critical input of project proposals submitted to CTI from academic institutions including outreach to PIs on projects of interest.

Emerging Science & Innovation group within Discovery Sciences • Project leader for small molecule drug discovery efforts on novel oncology targets implicated in tumor metabolic pathways and regulation of RNA editing. • Compose project proposal, workplan, and timelines for new drug discovery targets. Conception and reduction to practice of target validation studies, biochemical assays, and cell-based assays. • Coordinate and collaborate with multiple functional areas to drive projects forward, including legal/FTO, functional genetics, enzymology, protein crystallography, computational chemistry, high-throughput screening, compound logistics, as well as external CROs. • Successful design and execution of HTS plan for biochemical enzyme screening encompassing hit triage, selectivity assays, technology interference and orthogonal activity assays, biophysical assays, cell-based assays for viability & proliferation, cellular reporter assays, and close work with chemistry colleagues for SAR to define a hit-to-lead strategy. • Initiation of high-content imaging phenotypic screening platform to quantify features of cellular morphology to identify small molecules that promote desired phenotypes; direct secondary assays to validate drug efficacy. Collaboration with academic researcher to extend findings. • Initiate and drive collaborations with academic KOLs to externally screen Janssen compound libraries on enzyme targets of interest. • Manage postdoctoral researcher and research scientist with focus on high quality, detail-oriented data generation for project activities as well as professional development and growth.

Established yeast-based library screening platform to identify variants of Influenza hemagglutinin protein with improved characteristics to specifically focus immune response as vaccine antigens. • Designed and constructed high quality combinatorial libraries of hemagglutinin variants • Devised a novel screening platform and associated assays to assess library variants secreted from yeast; performed HTS of variants to identify and confirm top candidates • Active collaboration with Influenza vaccine team resulting in three patent applications and a publication Management of assay development team focused on functional characterization of therapeutic antibodies targeting various proteins implicated in human disease. • Ensure productivity, high quality data, adherence to timelines, and active engagement of employees • Successful optimization of cell based and in vitro assays to assess therapeutic potential of antibodies for disease intervention • Collaborate with antibody discovery and in vivo proof of concept groups to design and implement strategies to identify lead antibody candidates Project leader for antibody discovery program focused on a cardiovascular disease target. • Defined experimental strategy to identify antibodies with desired binding properties and characterize for functional therapeutic potential within projected timelines • Coordinate diverse teams (legal, antibody discovery, proof-of-concept) for execution of project activities

Development and optimization of a phage display antibody discovery platform to isolate and characterize novel human antibodies with therapeutic potential against microbial pathogens. -Developed and validated methods to isolate human antibody variants by screening randomized phage display libraries against microbial antigens -Designed randomization strategies for combinatorial phage display libraries -Increased library quality by implementing functional selection of antibody displaying phage -Successfully identified a panel of candidate antibodies to several nosocomial pathogens -Developed cell based assays to measure antibody binding by ELISA and flow cytometry -Characterized therapeutic potential of antibodies with primary human cell based functional assays to test complement fixation and activation of phagocytosis (CDC, ADCC, ADCP) -Performed transient transfection and purification of antibodies from mammalian cells -Performed FPLC analysis and ion exchange purifications of antibodies from aggregates -Managed a collection of microbial clinical isolates and developed appropriate growth conditions for each -Managed a team of scientists, trained fellow researchers, assembled SOP documents -Co-inventor on new patent application for antibody variants

Independent research project focused on analysis of cell cycle regulated phosphorylation of a transcriptional repressor and its impact on cell division in the yeast S. cerevisiae. -Utilized genetic techniques to create gene knockout or knock-in strains of yeast -Developed genetic assays to detect synthetic lethal interactions between mutant gene alleles -Cloned, expressed, and purified proteins for in vitro analysis of phosphorylation state using Western Blot, 2D gel-IEF, and radioisotope labeling -Analyzed cell cycle progression in yeast and mammalian cells by flow cytometry, quantitative-PCR, in vitro kinase assays, and fluorescence microscopy -Coordinated collaborative efforts between different laboratories contributing to the project -Collaborated with a postdoctoral researcher to determine the apoptotic properties of viral protein VP3 in mammalian cells; utilized mammalian tissue culture and transfection, apoptosis assays, protein purification, and protein transduction.

Primary research objective was to determine the functional promoter elements and transcription start sites of an interferon inducible gene, ADAR1. -Screened and sequenced cDNA libraries to identify three different transcriptional isoforms of the gene -Confirmed by Southern Blot existence and positioning of alternative Exon 1 sequences in the genome

Training Grant Awards: -Training Grant Program in Basic Clinical Genetics, NIH, UCSD; trainee (2002-2006) -Cancer Cell Biology Training Grant, NCI, UCSD; trainee (2001-2002) Teaching Experience: -Course Coordinator, Graduate Seminars in Cancer Biology (2008). -Guest Lecture, UC San Diego, Graduate Seminar in Biomedical Research (2006). -Teaching Assistant, UC San Diego, Undergraduate Genetics (2004).

Educational Honors: -Academic Excellence Award, UCSB, GPA 3.98 (2001) -College Honors, College of Letters and Science, UCSB (2001) -Distinction in the Major, Cell and Developmental Biology, UCSB (2001) -Beatrice M. Sweeny Award in Biological Sciences (2001) -Robert L. Sinsheimer Award in Molecular Biology (2001) -Robert C. Byrd Memorial Honors Scholarship, State of California (1997-2001) -Dean’s Honors List, UCSB (1997-2001) -College Honors Program, UCSB (1998-2001) -Alpha Lambda Delta Honor Society, Member -Golden Key International Honor Society, Member